In mouse models of non-alcoholic fatty liver disease (NAFLD) and NASH, FGF21 and its analogs have been shown to act as hepatoprotective factors by directly regulating hepatic lipid and free fatty acid metabolism. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.